Market Place
Sourcing Support
Molecure & Ocean Bio Sign Licensing Agreement For YKL-40 Inhibitors
15 Oct 2024 //
GLOBENEWSWIRE
Avicenna And Molecure Sign Research Collaboration Agreement
31 Jul 2024 //
BUSINESSWIRE
Molecure Approved For OATD-01 Pulmonary Sarcoidosis Phase 2 In EU, Norway
21 May 2024 //
GLOBENEWSWIRE
Molecure has Published Its Financial Report for 2023
03 Apr 2024 //
GLOBENEWSWIRE
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in PS
22 Mar 2024 //
GLOBENEWSWIRE
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
31 Oct 2023 //
GLOBENEWSWIRE
Molecure Announces First Half 2023 Results Significant Financial Momentum
29 Sep 2023 //
GLOBENEWSWIRE
FDA Gives Green Light to Molecure`s Program PII Testing of OATD-01 for Launch
24 Jul 2023 //
GLOBENEWSWIRE
Molecure completes successful SPO of approximately PLN 50 million
21 Jul 2023 //
GLOBENEWSWIRE
Molecure gears up for Phase II sarcoidosis trial
23 Jun 2023 //
CLINICAL TRIALS ARENA
Molecure Files an (IND) application for lead clinical candidate OATD-01
23 Jun 2023 //
GLOBENEWSWIRE
Molecure Announces Full Year Financial 2022 Results
30 Mar 2023 //
GLOBENEWSWIRE
Molecure Appoints Dr. Samson Fung, Chief Medical Officer
03 Jan 2023 //
PR NEWSWIRE
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
30 Oct 2022 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.